Erratum to: Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

Masashi Niwakawa · Katsuyoshi Hashine · Raizo Yamaguchi · Hirofumi Fujii ·
Yasuo Hamamoto · Koichi Fukino · Takahiko Tanigawa · Yoshiteru Sumiyoshi

Published online: 9 December 2011
© Springer Science+Business Media, LLC 2011

Erratum to: Invest New Drugs DOI 10.1007/s10637-010-9630-0

The original version of the article unfortunately contained two errors;

1) In the right half of Table 2, the adverse events listed for Cohort 3 had been erroneously deleted during production. Please refer to the next page for the corrected Table 2.

2) Subtype of the recombinant interferon α used in this study was erroneously described in Summary as interferon α -2a, which should be interferon α -2b instead.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-010-9630-0>.

M. Niwakawa (✉) · R. Yamaguchi
Division of Urology, Shizuoka Cancer Center Hospital,
1007 Shimonagakubo, Nagaizumi,
Shizuoka 411-8777, Japan
e-mail: m.niwakawa@scchr.jp

K. Hashine · Y. Sumiyoshi
Department of Urology, National Hospital Organization,
Shikoku Cancer Center,
Ehime, Japan

H. Fujii
Division of Clinical Oncology, Jichi Medical University,
Tochigi, Japan

Y. Hamamoto
Department of Medical Oncology,
Tochigi Cancer Center Hospital,
Tochigi, Japan

K. Fukino · T. Tanigawa
Bayer Yakuhin, Ltd.,
Osaka, Japan

Present Address:
R. Yamaguchi
Department of Urology, Teikyo University School of Medicine,
Tokyo, Japan

Table 2 Observed DLTs and adverse events resulting in permanent discontinuation of study medication

Observed DLTs in each cohort			AEs resulting in permanent discontinuation of study medication		
Cohort	Numbers of patients with DLTs	DLTs with CTCAE worst grade	Cohort	Numbers of patients who were off study drugs permanently due to AEs ^a	AEs with CTCAE worst grade
1	1	Fatigue, grade 3 (<i>n</i> =1)	1	3	AST, grade 3 (<i>n</i> =1) ALT, grade 3 (<i>n</i> =1) Pain, abdomen NOS, grade 4 (<i>n</i> =1) Hemoglobin, grade 5 (<i>n</i> =1) Platelets, grade 5 (<i>n</i> =1)
2	2	Pruritus, grade 3 (<i>n</i> =1) Hand-foot skin reaction grade 3 (<i>n</i> =1) Erythema multiforme, grade 3 (<i>n</i> =1) Fatigue, grade 3 (<i>n</i> =1)	2	2	Pruritus, grade 3 (<i>n</i> =1) Hand-foot skin reaction, grade 3 (<i>n</i> =1) Erythema multiforme, grade 3 (<i>n</i> =1) Mood alteration, depression, grade 3 (<i>n</i> =1) Hyponatremia, grade 4 (<i>n</i> =1)
3	2	Fatigue, grade 3 (<i>n</i> =2) Anorexia, grade 3 (<i>n</i> =1)	3	5	Anorexia, grade 3 (<i>n</i> =1) Fatigue, grade 3 (<i>n</i> =2) Psychosis, grade 3 (<i>n</i> =1) Hypertension, grade 3 (<i>n</i> =1) Lipase, grade 4 (<i>n</i> =1) Hemoglobin, grade 3 (<i>n</i> =1)

DLT dose-limiting toxicity, *AE* adverse event, *CTCAE* Common Terminology Criteria for Adverse Event, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *NOS* not otherwise specified

^a Patients were included who were off study medication due to disease progression during interruption of study medication